Compare GRFS & MIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRFS | MIR |
|---|---|---|
| Founded | 1940 | 2005 |
| Country | Spain | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 5.7B |
| IPO Year | 2006 | N/A |
| Metric | GRFS | MIR |
|---|---|---|
| Price | $9.24 | $25.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $10.15 | ★ $28.38 |
| AVG Volume (30 Days) | 465.4K | ★ 2.0M |
| Earning Date | 07-28-2022 | 02-10-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | 0.10 |
| Revenue | ★ $8,821,017,248.00 | $902,300,000.00 |
| Revenue This Year | $5.36 | $8.75 |
| Revenue Next Year | $5.15 | $23.17 |
| P/E Ratio | ★ $17.74 | $262.95 |
| Revenue Growth | 7.31 | ★ 7.82 |
| 52 Week Low | $6.19 | $12.00 |
| 52 Week High | $11.14 | $30.28 |
| Indicator | GRFS | MIR |
|---|---|---|
| Relative Strength Index (RSI) | 53.73 | 51.02 |
| Support Level | $8.63 | $25.73 |
| Resistance Level | $9.40 | $27.49 |
| Average True Range (ATR) | 0.23 | 1.09 |
| MACD | -0.02 | 0.11 |
| Stochastic Oscillator | 64.36 | 50.54 |
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.